Stocktoria

LENSAR, Inc. LNSR

Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
2/9
Piotroski F — financial health
-10.17
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$51.7M-$34.3M-$14.9M-$26.0M
2024$46.0M-$31.4M-$2.4M$4.9M
2023$42.2M-$14.4M-$9.9M$33.4M
2022$29.4M-$19.9M-$15.0M$42.0M
2021$34.5M-$19.6M-$9.3M$54.9M
2020$22.8M-$19.8M-$14.2M$67.2M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
HAMMER TODD Bdirector2026-06-03Grant17,421
ELLIS THOMAS Bdirector2026-06-03Grant17,421
Wong KendraPrincipal Accounting Officer2026-06-03Grant13,066
Connaughton Alan B.Chief Operating Officer2026-06-03Grant34,843
CURTIS NICHOLAS TChief Executive Officer2026-06-03Grant130,662
WEISNER AIMEE Sdirector2026-06-03Grant17,421
O'Farrell Elizabeth G.director2026-06-03Grant17,421
Winer Gary Mdirector2026-06-03Grant17,421

Why these scores methodology →

Piotroski F-score: 2/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -10.17 (distress)

  • Working capital / assets 0.087
  • Retained earnings / assets -2.486
  • EBIT / assets -0.344
  • Equity / liabilities -0.311

Source: SEC EDGAR filings · CIK 0001320350 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.